{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:03:42Z","timestamp":1772751822154,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,18]],"date-time":"2015-01-18T00:00:00Z","timestamp":1421539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s10555-014-9536-y","type":"journal-article","created":{"date-parts":[[2015,1,17]],"date-time":"2015-01-17T04:51:29Z","timestamp":1421470289000},"page":"5-10","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma"],"prefix":"10.1007","volume":"34","author":[{"given":"Shelly M.","family":"Seward","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Winer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,18]]},"reference":[{"key":"9536_CR1","unstructured":"Cancer Facts & Figures. (2014). Atlanta: American Cancer Society; 2014."},{"key":"9536_CR2","doi-asserted-by":"crossref","unstructured":"Buys, S.S., Partridge, E., Black, A., Johnson, C.C., Lamerato, I., Isaacs, C. (2011). Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. Journal of the American Medical Association. 2295\u2013303.","DOI":"10.1001\/jama.2011.766"},{"key":"9536_CR3","doi-asserted-by":"crossref","unstructured":"Menon, U.G-M.A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Davies, S., Philpott, S., Lopes, A., Godfrey, K., Oram, D., Herod, J., Williamson, K., Seif, MW., Scott, I., Mould, T., Woolas, R., Murdoch, J., Dobbs, S., Amso, NN., Leeson, S., Cruickshank, D., et al. (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology. 327\u201340.","DOI":"10.1016\/S1470-2045(09)70026-9"},{"key":"9536_CR4","doi-asserted-by":"crossref","unstructured":"Kurman, R.J., Shih, I.M. (2011). Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2014shifting the paradigm. Human Pathology. 918\u201331.","DOI":"10.1016\/j.humpath.2011.03.003"},{"key":"9536_CR5","unstructured":"Griffiths, C. (1975). Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. National Cancer Institute Monographs. 101\u20134."},{"issue":"2","key":"9536_CR6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","volume":"47","author":"WJ Hoskins","year":"1992","unstructured":"Hoskins, W. J., Bundy, B. N., Thigpen, J. T., & Omura, G. A. (1992). The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study. Gynecologic Oncology, 47(2), 159\u201362.","journal-title":"Gynecologic Oncology"},{"key":"9536_CR7","doi-asserted-by":"crossref","unstructured":"Hoskins, W.J., Creasman, M.W., Grady, M.F., Homesley, H.D., Creasman, W.T., Berman, M., Ball, H., Berek, J.S. (1994). The effect of tumor diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology. 974\u20139.","DOI":"10.1016\/S0002-9378(94)70090-7"},{"issue":"20","key":"9536_CR8","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.2007.11.0932","volume":"25","author":"AN Fader","year":"2007","unstructured":"Fader, A. N., & Rose, P. (2007). Role of surgery in ovarian carcinoma. Journal of Clinical Oncology, 25(20), 2873\u201383.","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"9536_CR9","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow, R. E., Tomacruz, R., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology, 20(5), 1248\u201359.","journal-title":"Journal of Clinical Oncology"},{"key":"9536_CR10","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1245\/s10434-012-2446-8","volume":"19","author":"SJ Chang","year":"2012","unstructured":"Chang, S. J., Bristow, R., & Ryu, H. S. (2012). Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in ovarian cancer. Annals of Surgical Oncology, 19, 4059\u201367.","journal-title":"Annals of Surgical Oncology"},{"issue":"24","key":"9536_CR11","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","volume":"25","author":"WE Winter","year":"2007","unstructured":"Winter, W. E., Maxwell, G., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., Markman, M., Armstrong, D. K., Muggia, F., & McGuire, W. P. (2007). Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology study group. Journal of Clincial Oncology, 25(24), 3621\u20137.","journal-title":"Journal of Clincial Oncology"},{"key":"9536_CR12","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A Bois du","year":"2009","unstructured":"du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., & Pfisterer, J. (2009). Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer, 115, 1234\u201344.","journal-title":"Cancer"},{"key":"9536_CR13","doi-asserted-by":"crossref","unstructured":"Elattar, A., Bryant, A., Winter-Roach, B.A., Hatem, M., Naik, R. (2011). Optimal primary surgical treatment for advanced epithelial ovarian cancer (Review). Cochrane Database Systematic Review. 2011.","DOI":"10.1002\/14651858.CD007565.pub2"},{"issue":"3 Suppl 7","key":"9536_CR14","first-page":"31","volume":"27","author":"IB Vergote","year":"2000","unstructured":"Vergote, I. B., De Wever, I., Decloedt, J., Tjalma, W., Van Gramberen, M., & van Dam, P. (2000). Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Seminars in Oncology, 27(3 Suppl 7), 31\u20136.","journal-title":"Seminars in Oncology"},{"issue":"1","key":"9536_CR15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1006\/gyno.1994.1083","volume":"53","author":"PE Schwartz","year":"1994","unstructured":"Schwartz, P. E., Chambers, J. T., & Makuch, R. (1994). Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology, 53(1), 33\u20137.","journal-title":"Gynecologic Oncology"},{"key":"9536_CR16","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","volume":"103","author":"R Bristow","year":"2006","unstructured":"Bristow, R., & Chi, D. S. (2006). Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecologic Oncology, 103, 1070\u20136.","journal-title":"Gynecologic Oncology"},{"key":"9536_CR17","author":"JO Schorge","year":"2014","unstructured":"Schorge, J. O., Clark, R., Lee, S. I., & Penson, R. T. (2014). Primary debulking surgery for advanced ovarian cancer: are you a believer or dissenter? Gynecologic Oncology. doi: 10.1016\/j.ygyno.2014.10.007 .","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"9536_CR18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","volume":"107","author":"GD Aletti","year":"2006","unstructured":"Aletti, G. D., Dowdy, S., Gostout, B. S., Jones, M. B., Stanhope, C. R., Wilson, T. O., Podratz, K. C., & Kliby, W. A. (2006). Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology, 107(1), 77\u201385.","journal-title":"Obstetrics and Gynecology"},{"issue":"10","key":"9536_CR19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"ITC Vergote","year":"2010","unstructured":"Vergote, I. T. C., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H., van der Burg, M., Lacave, A. J., Panici, P. B., Kenter, G. G., Casado, A., Mendiola, C., Coens, C., Verleye, L., Stuart, G., Pecorelli, S., & Reed, N. (2010). Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine, 363(10), 943\u201353.","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"9536_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire, W. P., Hoskins, W., Brady, M. F., Kugera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. New England Journal of Medicine, 334(1), 1\u20136.","journal-title":"New England Journal of Medicine"},{"key":"9536_CR21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine, 354, 34\u201343.","journal-title":"New England Journal of Medicine"},{"key":"9536_CR22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2011.08.014","volume":"124","author":"DS Chi","year":"2012","unstructured":"Chi, D. S., Musa, F., Dao, F., Zivanovic, O., Sonoda, Y., Leitao, M., Levine, D., Gardner, G., Abu-Rustum, N., & Barakat, R. (2012). An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecologic Oncology, 124, 10\u20134.","journal-title":"Gynecologic Oncology"},{"key":"9536_CR23","unstructured":"Kehoe, S., Hook, J., Nankivell, M., et al. (2013). Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial.; 2013; Chicago: 2013 ASCO Annual Meeting, Abstract 5500."},{"key":"9536_CR24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2005.07.123","volume":"100","author":"GD Aletti","year":"2006","unstructured":"Aletti, G. D., Gostout, B., Podratz, K. C., & Cliby, W. A. (2006). Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecologic Oncology, 100, 33\u20137.","journal-title":"Gynecologic Oncology"},{"key":"9536_CR25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1006\/gyno.2001.6313","volume":"82","author":"SM Eisenkop","year":"2001","unstructured":"Eisenkop, S. M., & Spirtos, N. (2001). Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with \u201cbiological aggressiveness\u201d and survival? Gynecologic Oncology, 82, 435\u201341.","journal-title":"Gynecologic Oncology"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-014-9536-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10555-014-9536-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-014-9536-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:20:15Z","timestamp":1559236815000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10555-014-9536-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,18]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["9536"],"URL":"https:\/\/doi.org\/10.1007\/s10555-014-9536-y","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,18]]}}}